ĐẶC ĐIỂM BIỂU HIỆN CỦA CDX2 Ở BỆNH NHÂN CARCINÔM TUYẾN ĐẠI - TRỰC TRÀNG TẠI VIỆT NAM

Abstract

Objective: To evaluate the association between CDX2 expression and clinicopathological features in colorectal adenocarcinoma. Materials and Methods: A cross-sectional study was conducted on 356 cases. CDX2 expression was assessed using a cut-off of ≥25% tumor cell nuclear positivity. Results: CDX2 positivity was observed in 95.8% of cases, with no significant differences according to sex, age, tumor location, nodal status, or histological subtype. Notably, tumors in stages T1–T3 demonstrated a significantly higher rate of CDX2 expression compared with advanced tumors in stages T4a–T4b (OR=4.53; p<0.005), underscoring a strong association between tumor invasion depth and loss of CDX2 expression. In addition, there was a trend toward increased risk of CDX2 loss in poorly differentiated tumors compared with moderately differentiated tumors (OR=1.63; 95% CI: 0.20–13.6), suggesting that CDX2 may serve as a potential biomarker reflecting both tumor aggressiveness and prognosis. Conclusion: CDX2 is expressed at a remarkably high frequency in colorectal adenocarcinoma; however, its marked reduction in T4 tumors highlights its role as a pivotal marker of tumor invasion and prognostic significance.